跳至主要内容
临床试验/NCT01603329
NCT01603329已完成不适用

Increasing Medication Adherence Through Physician Incentives and Messaging

National Bureau of Economic Research, Inc.1 个研究点 分布在 1 个国家目标入组 734 人开始时间: 2012年6月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
734
试验地点
1
主要终点
Medication Adherence

研究概览

简要总结

The goal of this project is to increase patient adherence to medication using communications and incentives for physicians. The investigators are partnering with a health insurance company, Humana Inc, to design and implement an incentives program for physicians whose patients increase their medication adherence for oral diabetes medication, hypertension (ACEI or ARB) medication, and/or cholesterol (statins) medication. The investigators will use behavioral economics to explore the best way to communicate the incentives to the physicians.

详细描述

Traditional economics would suggest that the best way to maximize adherence would be to give physicians financial incentives to improve adherence to all relevant drugs, and that communications to physicians should emphasize all of the relevant drugs. Behavioral economics suggests theory suggests that if you emphasize everything, then you are effectively emphasizing nothing. Behavioral econonmics would suggest to maximize adherence one should give physicians financial incentives for improving adherence for a small number of relevant drugs, and communications to physicians should emphasize a small number of the relevant drugs. This allows physicians to focus their energy and reduces the probability that they will give up because they're overwhelmed, or in other words, avoid the phenomenon called metric fatigue.

Humana has already implemented an incentives program for physicians, and the investigators will work with them to design a program that just focuses on medication adherence. Physicians targeted for this pilot could also be enrolled in another Humana incentives program, but this incentives program will act independently of the other.

There are two treatment dimensions the investigators will test via random assignment at the practice level:

  1. Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.
  2. Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.

In a previous study to increase uptake of colonoscopies among employees at a partner firm, the investigators found that using a post it note to catch the attention of the employee statistically significantly increased colonoscopy uptake over a control group. The investigators will also employ an eye catching method in the proposed pilot. When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. They will be encouraged to include the patient sheet in their chart as a reminder to discuss medication adherence with their patient the next time they see them. For half of our arms, the investigators will make the patient sheets a bright, non-white, color, in order to futher draw the physicians' attention to that specific paper in their chart.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Physician in the Humana network
  • •Treats Humana Medicare Advantage Members
  • •Has Humana Medicare Advantage members who are taking at least one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and/or cholesterol (statins) medication, and who are less than 80% adherent.

排除标准

  • •Practices with more than 10 physicians

研究组 & 干预措施

Comprehensive incentives + comprehensive communication

Experimental

Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.

干预措施: Increasing Medication Adherence through Physician Incentives and Messaging (Other)

Comp incentives + comp communication + non-white paper

Experimental

Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication, and their patient reports are printed on non-white bright colored paper.

干预措施: Increasing Medication Adherence through Physician Incentives and Messaging (Other)

Focused incentives + focused com for oral diabetes medication

Experimental

Physicians are given financial incentives for improving patient medication adherence for oral diabetes medication.

干预措施: Increasing Medication Adherence through Physician Incentives and Messaging (Other)

Foc incentives + foc comm for Diabetes + non-white paper

Experimental

Physicians given financial incentives for improving patient medication adherence for oral diabetes medication and patient reports are printed on bright non-white paper.

干预措施: Increasing Medication Adherence through Physician Incentives and Messaging (Other)

Focused incentives + focused comm for hypertension meds

Experimental

Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication.

干预措施: Increasing Medication Adherence through Physician Incentives and Messaging (Other)

Foc incentives + comm for hypertension meds + non-white paper

Experimental

Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication with patient reports on non-white paper.

干预措施: Increasing Medication Adherence through Physician Incentives and Messaging (Other)

Focused incentives + focused comm for cholesterol meds

Experimental

Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication.

干预措施: Increasing Medication Adherence through Physician Incentives and Messaging (Other)

Foc incentives +comm for cholesterol meds + non-white paper

Experimental

Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication and patient reports are printed on non-white paper.

干预措施: Increasing Medication Adherence through Physician Incentives and Messaging (Other)

Comprehensive communiation

Experimental

Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.

干预措施: Increasing Medication Adherence through Physician Incentives and Messaging (Other)

Comprehensive communication + non-white paper

Experimental

Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication and patient reports are printed on non-white paper.

干预措施: Increasing Medication Adherence through Physician Incentives and Messaging (Other)

Control Arm

Experimental

Physicians and their patient adherence is tracked, but they receive no intervention.

干预措施: Increasing Medication Adherence through Physician Incentives and Messaging (Other)

结局指标

主要结局

Medication Adherence

时间窗: Up to two years

The investigators will see how the treatment arms affect the targeted physicians' patients medication adherence for oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.

次要结局

  • Demographic Controls for Physicians(Up to two years)
  • Demographic Controls for Patients(Up to 2 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验